RMD vs PHG Stock Comparison: AI Score, Valuation, Performance and Upside
RMD (ResMed) is the global sleep apnea and respiratory care device leader with connected cloud capabilities, dramatically benefiting from the Philips Respironics device recall that transferred millions of patients to ResMed devices. PHG (Philips) is a diversified healthcare technology company managing the fallout from the Respironics recall while maintaining leadership in medical imaging and hospital monitoring.
RMD vs PHG in sleep apnea is market-share winner (ResMed captures Philips recall patients) versus diversified healthcare conglomerate managing recall crisis (Philips rebuilds Respironics while leveraging imaging and monitoring businesses) — one of the most consequential medical device market share shifts in recent history.
PHG holds the edge across 3 of 5 key metrics in this comparison. PHG leads on both 1-year return (-2.36%) and forward P/E quality (13.11x vs 18.18x for RMD), a relatively favorable combination of momentum and valuation. RMD leads on both revenue growth (8.60%) and operating margin (30.86%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for PHG (+29.05%) than for RMD (+2.15%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want the global leader in sleep apnea devices with connected cloud capabilities, sustained market share gains from the Philips recall, and growing SaaS revenue from care management platforms
- Value ResMed's near-monopoly market share during Philips's supply constraints as creating patient loyalty and data network effects that may persist beyond the recall period
- See home respiratory care and sleep apnea as structural growth markets as diagnosis rates improve and the obesity-sleep apnea connection drives treatment demand
- Want diversified healthcare technology exposure through Philips's medical imaging, patient monitoring, and connected care businesses at a valuation reflecting recall disruption
- Value Philips's medical imaging (MRI, CT, ultrasound) as a high-quality, recurring-service business that is separate from the Respironics recall impact and remains a strong franchise
- See Philips's recall resolution and litigation settlement as a clearing event that could unlock significant valuation recovery for the broader healthcare technology portfolio
| Metric | RMD | PHG |
|---|---|---|
| AI scorei | 50.2 | 28.0 |
| AI ranki | #485 | #2309 |
| Latest closei | $222.00 | $24.96 |
| 1M returni | -5.81% | -7.52% |
| 6M returni | +0.69% | -3.16% |
| 1Y returni | -19.03% | -2.36% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RMD | PHG |
|---|---|---|
| 1Y ago | $8.3K (-17.0%) started 2025-09-25 | $10.15K (+1.5%) started 2025-09-25 |
| 5Y ago | $8.77K (-12.3%) started 2021-09-27 | $6.97K (-30.3%) started 2021-09-27 |
| 10Y ago | $42.7K (+327.0%) started 2016-09-26 | $13.07K (+30.7%) started 2016-09-26 |
Hypothetical — past performance does not guarantee future results.
| Metric | RMD | PHG |
|---|---|---|
| Market capi | $34.67B | $24.4B |
| Trailing P/Ei | 23.04 | 19.05 |
| Forward P/Ei | 18.18 | 13.11 |
| Price/Salesi | N/A | 1.38 |
| EV/Revenuei | 6.02 | 1.70 |
| Analyst targeti | $245.50 | $32.21 |
| Target upsidei | +2.15% | +29.05% |
| Metric | RMD | PHG |
|---|---|---|
| Revenue growthi | 8.60% | 0.50% |
| Earnings growthi | 2.40% | 61.40% |
| EPS growthi | +2.40% | +61.40% |
| FCF margini | +16.61% | +8.65% |
| Operating margini | 30.86% | 13.99% |
| Profit margini | 26.95% | 6.31% |
| ROIC proxyi | 24.27% | 10.15% |
| Return on equityi | 24.27% | 10.15% |
| Dividend yieldi | 1.10% | 4.06% |
| Payout ratioi | 23.01% | 76.21% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.75 | 0.91 |
| Debt/equityi | 12.54 | 65.05 |
| Current ratioi | 3.10 | 1.26 |
| Quick ratioi | 1.83 | 0.73 |
Over the past year, RMD and PHG have moved weakly in the same direction (correlation of 0.31), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RMD | PHG |
|---|---|---|---|
| 1Y | Growthi | -16.95% | -2.36% |
| CAGRi | -16.97% | -2.36% | |
| Volatilityi | 28.47% | 28.16% | |
| Sharpe ratioi | -0.67 | -0.11 | |
| Sortino ratioi | -0.89 | -0.15 | |
| Max drawdowni | 35.46% | 22.81% | |
| Current drawdowni | 21.63% | 21.20% | |
| Avg drawdowni | 17.53% | 11.00% | |
| Ulcer Indexi | 19.63% | 12.99% | |
| Max daily dropi | 6.33% | 5.68% | |
| Max wkly dropi | 12.17% | 9.59% | |
| 5Y | Growthi | -15.19% | -38.40% |
| CAGRi | -3.25% | -9.25% | |
| Volatilityi | 31.78% | 37.62% | |
| Sharpe ratioi | -0.09 | -0.19 | |
| Sortino ratioi | -0.12 | -0.27 | |
| Max drawdowni | 49.42% | 74.59% | |
| Current drawdowni | 24.42% | 41.66% | |
| Avg drawdowni | 18.07% | 45.15% | |
| Ulcer Indexi | 21.15% | 47.12% | |
| Max daily dropi | 18.50% | 15.95% | |
| Max wkly dropi | 20.45% | 18.61% | |
| 10Y | Growthi | +285.11% | +4.23% |
| CAGRi | +14.44% | +0.41% | |
| Volatilityi | 31.84% | 31.91% | |
| Sharpe ratioi | 0.44 | 0.03 | |
| Sortino ratioi | 0.62 | 0.04 | |
| Max drawdowni | 53.99% | 79.61% | |
| Current drawdowni | 24.42% | 53.20% | |
| Avg drawdowni | 14.39% | 31.71% | |
| Ulcer Indexi | 19.09% | 40.99% | |
| Max daily dropi | 19.39% | 15.95% | |
| Max wkly dropi | 23.64% | 19.10% |
| Category | RMD | PHG |
|---|---|---|
| Company | ResMed Inc. | Koninklijke Philips N.V. |
| Sector | Healthcare | Healthcare - Diversified Medical Technology |
| Industry | Medical Instruments & Supplies | Medical Devices |
| Core business | ResMed is the global leader in cloud-connected sleep apnea devices — including CPAP (Continuous Positive Airway Pressure) machines, masks, and accessories — plus software-as-a-service (SaaS) solutions for remote patient monitoring (myAir app), care coordination, and out-of-hospital respiratory care management. | Philips is a Dutch healthcare technology conglomerate providing medical imaging (MRI, CT, ultrasound), image-guided therapy devices, patient monitoring, connected care software, and sleep and respiratory care (CPAP/BiPAP) — undergoing a major restructuring and recovery from the Philips Respironics device recall. |
| Investor focus | Investors track ResMed's device revenue (CPAP machines and masks), SaaS subscription revenue from care management platforms (Brightree, MatrixCare), gross margin, and the enormous patient opportunity created by Philips's device recall. | Investors track Philips's sleep and respiratory care recovery (Philips Respironics), order intake for imaging systems, margin recovery progress, legal settlement progress for the Respironics recall, and the Philips transformation plan execution. |
- Global #1 in sleep apnea devices with the most patient-connected cloud platform — millions of ResMed CPAP users transmit sleep data nightly through myAir, enabling remote compliance monitoring
- Philips Respironics recall (over 5.5 million devices recalled for foam degradation risk) dramatically shifted market share to ResMed — the primary beneficiary of the largest medical device recall in sleep apnea history
- SaaS business (Brightree, MatrixCare) for home health care coordination provides recurring software revenue independent of device sales cycles
- Diversified healthcare technology portfolio spanning imaging, monitoring, and connected care provides multiple revenue streams across the hospital and homecare settings
- Medical imaging (MRI, CT, ultrasound) is a high-margin, recurring-service business — hospitals rely on Philips imaging systems and require ongoing maintenance, service, and upgrade contracts
- European healthcare market strength through deep relationships with hospital networks across the Netherlands, Germany, and broader European market
- ResMed's device revenue is beginning to normalize as the Philips supply gap fills and demand catch-up moderates
- GLP-1 weight loss medications (Ozempic, Wegovy) may reduce the prevalence of obesity-related sleep apnea — a potential long-term headwind if weight loss therapy reduces the patient population needing CPAP
- Healthcare at-home and care coordination SaaS is increasingly competitive — Brightree and MatrixCare compete with other home health software vendors
- Philips Respironics recall has resulted in billions of euros in recall-related charges, ongoing litigation, and reputational damage in the sleep apnea market where it was previously the leader
- The sleep device market share lost to ResMed during the recall period has been very difficult to recover — many patients switched to ResMed and have not returned to Philips
- Philips ADR (PHG) trades on OTC markets for U.S. investors, with the primary listing on Euronext Amsterdam — U.S. investors face EUR/USD currency exposure
Compare more than two at a time
This page is a fixed writeup on RMD and PHG. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside RMD and PHG, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.